First-line treatment with the PD-1 inhibitor pembrolizumab showed an overall survival benefit compared to platinum-based chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer and… read more.
With permutations of potential front-line treatments for non-small cell lung cancer (NSCLC) seemingly endless, one thing seems certain…
Hot topics in lung cancer – interviews from ASCO 2018.
June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.
Survival was more than 2 years shorter in breast, prostate cancers. Patients with rheumatoid arthritis (RA) had a 40% to 50% increased mortality risk if they developed breast… read more.
Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.
Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.
by Bruce Sylvester: Investigative rovalpituzumab tesirine (Rova-T) appears to be safe and shows efficacy in treating advanced small cell lung cancer (SCLC), researchers reported in June, 2016 at… read more.
by Gary Finnegan: Six medicines, including two combination therapies for chronic hepatitis C, have been recommended for approval at the May meeting of the European Medicines Agency’s Committee for… read more.
Done correctly, living donation success is possible by Thomas R. Collins Life expectancy and quality of life measures tend to be quite high among live liver donors, generally… read more.
Done correctly, living donation success is possible by Thomas R. Collins Life expectancy and quality of life measures tend to be quite high among live liver donors, generally… read more.
by Gary Finnegan: Good news in the battle against cancer: death rates from leukaemia among people of all ages in Europe are falling.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
